Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the AURKA shRNA guide strand refers to a heterogeneous group of unintended transcripts that are downregulated during RNA interference (RNAi) experiments targeting Aurora Kinase A (AURKA). This phenomenon occurs when the shRNA guide strand acts as a microRNA, binding to the 3' untranslated regions (UTRs) of mRNAs that share complementarity with its 6-8 nucleotide 'seed' sequence (Jackson et al., 2003). Because AURKA is a critical regulator of mitosis, researchers frequently use shRNAs to study its function; however, the resulting phenotypes, such as mitotic arrest or cell death, can sometimes be caused by these off-target effects rather than the loss of AURKA itself (Birmingham et al., 2006). These unintended interactions represent a significant challenge in drug development and functional genomics, as they can lead to unforeseen toxicities and complicate the interpretation of preclinical data. Strategies to mitigate these effects include the use of multiple independent shRNAs, chemical modifications to the guide strand, and rigorous validation using rescue experiments with shRNA-resistant cDNA (Sigoillot et al., 2012). Consequently, these mRNAs are viewed as a source of experimental noise and potential safety risk rather than viable therapeutic targets.
Suppression of unintended gene expression via seed-sequence complementarity (nucleotides 2-8) in the 3' untranslated region (UTR) of mRNAs, mimicking microRNA-mediated translational repression or degradation through the RNA-induced silencing complex (RISC) (Jackson et al., 2003; Birmingham et al., 2006).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to the AURKA shRNA guide strand (AURKA shRNA off-targets).